Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Total Debt (2021 - 2025)

Precision Biosciences (DTIL) has disclosed Total Debt for 4 consecutive years, with $22.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Debt changed 0.43% to $22.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.4 million, a 0.43% change, with the full-year FY2024 number at $22.3 million, changed 0.41% from a year prior.
  • Total Debt was $22.4 million for Q3 2025 at Precision Biosciences, roughly flat from $22.4 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $22.5 million in Q2 2024 to a low of $2.4 million in Q2 2021.
  • A 4-year average of $19.0 million and a median of $22.3 million in 2025 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: increased 0.79% in 2024, then fell 0.62% in 2025.
  • Precision Biosciences' Total Debt stood at $2.5 million in 2021, then surged by 813.28% to $22.4 million in 2023, then decreased by 0.41% to $22.3 million in 2024, then grew by 0.24% to $22.4 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Total Debt are $22.4 million (Q3 2025), $22.4 million (Q2 2025), and $22.3 million (Q1 2025).